Prophylaxis of cytomegalovirus (CMV) reactivation & disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).
Monitor CVM DNA on wkly basis. Concomitant use w/ CYP3A substrates w/ narrow therapeutic ranges eg, alfentanil, fentanyl, quinidine. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May affect ability to drive & use machines. Not recommended in severe hepatic impairment; moderate hepatic impairment w/ moderate or severe renal impairment. ESRD w/ or w/o dialysis. Not recommended in women of childbearing potential & during pregnancy. Lactation. Childn <18 yr.
Sign Out
